Patients with high-grade atrioventricular block treated and not treated with a pacemaker

Permanent pacemaker treatment in older age groups

Of 693 patients on permanent pacemaker treatment between 1962 and 1981, 282 (40.7%) were above the age of 75. Of this number, 142 patients were 75-79 years, 95 80-84 years and 45 85-93 (mean 87) years old at the time of the first pacemaker implantation. The patients were followed for 13-154 months (mean 37.1) with special attention being paid to morbidity and mortality after the implantation. Complications occurred in 65 (23%) of the elderly patients, with no significant difference between the three age groups. Excessive threshold rise with stimulation failure (6%) and infections or skin erosions (4.9%) were the most frequent complications. Mortality increased in all age groups during the first 6-12 months compared with the age- and sex-matched Norwegian population. Five-year survival rates were 56, 32 and 25% respectively. We conclude that cardiac pacemaker treatment in the elderly is a safe symptom-relieving therapeutic procedure and that the prognosis for these patients is similar to that for their fellow senior citizens after the first year of treatment.

Sick sinus syndrome treated with permanent pacemaker in 109 patients. A follow-up study

During the last decade implantation of permanent pacemakers has become the treatment of choice for patients suffering from the sick sinus syndrome (SSS). We have followed up 112 SSS patients treated with permanent pacemakers in Haukeland Hospital in the period 1966--76. The pacemakers were later removed from three of the patients. In the remaining 109 patients the SSS was characterized by tachy-bradyarrhythmias (TBA) in 44 and bradyarrhythmias (BA) in 65. Before implantation, 68 patients had syncopes and 27 severe dizziness. After implantation, symptomatic improvement was apparent in 104 patients; only three still had syncopes. During the follow-up period (mean 34.4 months), 29 patients died (yearly mortality 9.3%). There was no significant difference in total mortality between patients with TBA and with BA. Concomitant disturbances in atrioventricular (AV) conduction occurred in 35.8% of the patients. Among 79 of 80 patients still alive, five had developed total AV block, 19 had stable atrial fibrillation, 12 of these were possibly pacemaker-independent (ventricular rate greater than 60/min). Systemic embolization was observed in 16 patients, more frequently in the TBA (12/44) than in the BA group (4/65) (p less than 0.001). It is concluded that permanent pacemakers have an excellent symptomatic effect in patients with SSS. The prognosis is mainly determined by the presence or absence of coronary heart disease and/or heart failure.

Prospective randomized trials on pacing mode: what have we learned?

Retrospective studies and observational clinical data on pacemaker mode selection indicate that physiologic pacing is associated with better clinical outcomes and reduced mortality when compared with single-chamber ventricular pacing. Methodologic flaws in such studies, especially in respect of selection bias, have cast doubt upon the validity of the results and have mandated the performance of randomized, prospective studies of pacemaker-mode prescription. Evidence available to date suggests that atrial-based pacing may confer improved quality of life and a reduction in the incidence of chronic atrial fibrillation and thromboembolic events in sinus node disease. Physiologic pacing modes have, to date, not demonstrated benefit with congestive heart failure or patient longevity. The results of ongoing, large prospective trials of mode prescription in patients with AV block and sinus node disease are needed before any change from current guidelines can be recommended.

Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias

Cost-effectiveness analyses were reviewed in the following diagnostic and treatment categories: acute myocardial infarction (MI) and diagnostic strategies for coronary artery disease (CAD), coronary artery bypass graft (CABG) surgery, percutaneous transluminal coronary angioplasty (PTCA), congestive heart failure (CHF), and arrhythmias. In the case of acute MI, coronary care units, as presently used, are rather expensive but could be made much more efficient with more effective triage and resource utilization; reperfusion via thrombolysis is cost-effective, as are beta-blockers and angiotensin-converting enzyme (ACE) inhibitors post-MI in appropriate patients. Cost-effectiveness of CAD screening tests depends strongly on the prevalence of disease in the population studied. Cost-effectiveness of CABG surgery depends on targeting; eg, it is highly effective for such conditions as left-main and three-vessel disease but not for lesser disease. PTCA appears to be cost-effective in situations where there is clinical consensus for its use, eg, severe ischemia and one-vessel disease, but requires further analysis based on randomized data; coronary stents also appear to be cost-effective. In preliminary analysis, ACE inhibition for CHF dominates, ie, saves both money and lives. Cardiac transplant appears to be cost-effective but requires further study. For arrhythmias, implantable cardioverter defibrillators are cost-effective, especially the transvenous device, in life-threatening situations; radiofrequency ablation is also cost-effective in patients with Wolff-Parkinson-White syndrome apart from asymptomatic individuals; and pacemakers have not been analyzed except in the case of biofascicular block, where results were variable depending on the situation and preceding tests.

Long-term survival after pacemaker implantation for heart block in patients > or = 65 years

Permanent pacing can prevent recurrent symptoms and reduce mortality in elderly patients with symptomatic high-degree atrioventricular (AV) block. However, long-term survival with respect to comparable control subjects has not been well defined. In our study, relative long-term survival and prognostic predictors after permanent pacemaker implantation for symptomatic high-degree AV block were assessed among all residents of Olmsted County, Minnesota, who were > or = 65 years old. Of the 154 patients, 77 were men and 77 were women (mean age 80 +/- 7 years). Follow-up was 0.1 to 19.8 years (mean 4.2 +/- 2.8). Sixty-nine patients had isolated AV block and 85 had coexisting heart disease. Observed survival at 1, 3, 5, and 10 years was 85%, 68%, 52%, 21%, and 72%, 50%, 31%, 11% for patients with isolated AV block and patients with coexisting heart disease, respectively (p = 0.006). Observed survival in patients 65 to 79 years old with isolated AV block was comparable to age- and sex-matched cohorts (p = 0.53), but in patients aged > or = 80 years, it was less than that for control subjects (p = 0.014). In patients with coexisting heart disease, observed survival was less than that for control subjects in patients 65 to 79 years old (p < 0.001) and > or = 80 years (p < 0.001). Multivariate analysis identified congestive heart failure, chronic obstructive pulmonary disease, age, syncope, insulin-dependent diabetes mellitus, and male gender as independent predictors of increased mortality.

Prevalence, circumstances, mechanisms, and risk stratification of sudden cardiac death in unipolar single-chamber ventricular pacing

BACKGROUND

Permanent cardiac pacing is well established for the improvement of prognosis and quality of life in patients with severe bradycardia. However, sudden cardiac death still remains an unresolved problem, as it occurs in approximately 20-30% of paced patients. This 2-year follow-up study was directed at prospectively assessing prevalence, circumstances, and mechanisms of sudden death in 2,021 permanently paced patients.

METHODS AND RESULTS

During the observation period, 220 patients (11%) died (mean pacing interval, 50.5 +/- 7 months). Lethal cerebrovascular events in 66 of 220 patients (30%) and sudden death in 49 of 220 patients (23%) were the two most frequently reported modes of death. Nonsudden (first year, 20%; subsequent years, 6.9%; p less than 0.01) and sudden death mortality rate (4% versus 1.8%, p less than 0.05) were highest during the first year. Mortality was unrelated to the patient's activity status at the time of death. Sudden cardiac death occurred more often in male patients (increased risk, 1.7 versus female patients; p less than 0.001) and patients younger than 60 years of age (5.2 versus patients older than 60 years, p less than 0.001). Patients with severe bradycardia (sudden death rate, 28%), severe atrioventricular block (25%), or atrial fibrillation with low ventricular rate (25%) before pacemaker implantation were more likely to suffer from sudden cardiac death than patients with previous syncopal attacks (sudden death rate, 15%) or sick sinus syndrome (17%). The highest incidence of sudden death was observed in patients with bifascicular and trifascicular bundle branch block. In this group, 35% of patients died suddenly during the follow-up period compared with 18% of patients without bundle branch block. In a subsequent study in 90 consecutive patients with various types of bundle branch block, undersensing of up to 13% of ectopic ventricular beats occurred in patients with bifascicular block. Pacing-induced tachyarrhythmias and ventricular fibrillation were documented in 10% of undersensed ectopic ventricular beats as well as in the setting of atrial fibrillation associated with ventricular arrhythmias.

CONCLUSIONS

Young age, male sex, and a severely diseased heart indicated by the presence of bifascicular and trifascicular bundle branch block are the strongest predictive clinical parameters for sudden cardiac death, especially in the first year after pacemaker implantation.

Utility of ambulatory electrocardiography in detecting pacemaker dysfunction in the early postimplantation period

The value of ambulatory electrocardiography (AECG) in detecting pacemaker dysfunction before hospital discharge was assessed in 100 patients a mean of 1.2 days after pacemaker implantation. The incidence of permanent pacemaker dysfunction detected by AECG in the early postimplantation period, the frequency that pacemaker dysfunction detected by AECG was not detected by telemetric monitoring and the frequency that results of AECG led to pacemaker reprogramming before hospital discharge were determined. AECG detected at least 1 type of pacemaker dysfunction in 35% of patients and routine telemetry identified the abnormality in only 8% (p less than 0.001). Pacemaker dysfunction occurred in 42% of patients with dual-chamber devices and 27% of those with single-chamber devices (difference not significant). In the 35 patients who had pacemaker malfunction, a total of 50 instances of pacemaker dysfunction were detected. Failure of atrial capture occurred in 2% of patients, failure of atrial sensing in 9%, failure of atrial output in 1%, failure of ventricular capture in 8%, failure of ventricular sensing in 14%, failure of ventricular output due to myopotential inhibition in 11% and pacemaker-mediated tachycardia in 5%. The results of the AECG led to a clinical intervention in 22 patients (pacemaker reprogramming in 21 patients and lead repositioning in 1 patient) in whom no pacemaker dysfunction was suspected on the basis of telemetry or clinical symptoms. In conclusion, AECG provides additional benefit beyond that of routine telemetry monitoring in identifying pacemaker dysfunction in the early period after implantation.

A computer-based Markov decision analysis of the management of symptomatic bifascicular block: the threshold probability for pacing

This review illustrates the use of computer-based Markov models to estimate cost-effectiveness and prognosis in a complex problem in clinical cardiology. Decision analysis and cost-effectiveness analysis were used to assess whether to implant a permanent cardiac pacemaker, treat with drugs, perform electrophysiologic studies or observe patients who have two clinical features--syncope and bifascicular block--that may or may not be causally related. Using a Markov process model, a computer program simulated the prognosis of five cohorts of such patients--one treated conservatively, one given empiric antiarrhythmic drug therapy, one receiving a pacemaker, one treated with empiric drugs and pacing and one tested with electrophysiologic studies. On the basis of data from published reports and expert opinion, quality-adjusted life expectancy was calculated by summing the average time a member of each cohort would survive with and without symptoms for each initial treatment choice. The costs were estimated from 1985 hospital charges. For patients with normal left ventricular function, electrophysiologic testing provides a benefit of 14 quality-adjusted months of life over observation, at an additional cost of $24,200. Empiric pacing would add 2.5 additional months, at a further cost of $14,300. In patients with poor left ventricular function, empiric drug therapy offers 1.5 additional quality-adjusted months over observation, at a cost of $6,900. Electrophysiologic testing provides a further 16.5 months at an additional cost of $16,900. These results hold when the relation between symptoms and arrhythmia is not firmly established. Varying the probabilities of underlying ventricular tachyarrhythmias, bradyarrhythmic conduction defects or noncardiac causes of syncope affects the cost-effectiveness relative to the alternative treatments.

Spontaneous heart activity in pacemaker treated patients with high-grade atrioventricular block. A Holter monitor study

A Holter monitor study was performed to assess the occurrence of spontaneous heart activity in 70 pacemaker treated patients (mean age 72.1 years) with high-grade atrioventricular (AV) block, who have been treated with permanent pacemakers for a mean of 60 months (range 5-161). Nineteen patients had asynchronous (VOO), and 51 QRS-inhibited (VVI) pacemakers. The patients were monitored for a mean of 23 hours (range 15.5-26). Twenty-five patients were re-studied for day-by-day variations in spontaneous heart activity. At clinical observation, thirty-eight patients had some kind of spontaneous cardiac activity, mostly ventricular ectopic beats. Three patients had short episodes of sinus rhythm of more than 70 beats/min. Patients in functional class III-IV (NYHA) or with an enlarged heart had the most spontaneous heart activity. No tachyarrhythmias precipitated by interference between intrinsic heart beats and asynchronous pacemakers were seen. Twenty patients studied twice had a relatively stable occurrence of spontaneous heart activity, while five (20%) varied considerably. On the basis of these long-term observations it is difficult to predict when interference rhythm will occur, and asynchronous pacemakers therefore cannot be recommended for the first implantation.

Myopotential inhibition of unipolar QRS-inhibited (VVI) pacemakers, assessed by ambulatory Holter monitoring of the electrocardiogram

Seventy-four patients with unipolar QRS-inhibited pacemakers (VVI) were Holter monitored to assess the occurrence of pacemaker inhibition caused by skeletal muscle potentials during daily activities. Fifty patients had high-grade atrioventricular block and 24 had sinoatrial disease. Chest wall stimulation prior to monitoring revealed asystole of > 4 seconds duration in 22 patients, and ventricular rates between 25 and 56 beats per minute in 52 patients. Fifty-one patients (69%) had one or more episodes of pacemaker inhibition from myopotentials. Inhibition occurred in all types of pacemakers studies, but was most frequent and of longest duration in patients with Siemens-Elema 207/70 (13/14 patients), Cordis Omni-Stanicor (6/7 patients), CPI Microlith (5/6 patients), and Medtronic 5945 (8/10 patients). This was not unexpected considering the filter characteristics of the pacemakers. Nine patients (12%) presented symptoms which might be ascribed to pacemaker inhibition. The longest asystole observed was 3.2 s. Seven patients had pacemakers spikes falling on or near T-waves of spontaneous heart beats because their pacemakers had been rendered refractory by myopotentials. No serious arrhythmias were seen during episodes of pacemaker inhibition or interference. More emphasis should be put on the improvement of filter characteristics of unipolar VVI-pacemakers. Pacemaker patients with symptoms of myopotential inhibition should be equipped with either a bipolar or ventricular triggered (VVT) pacemaker or with a sensitivity and/or pacing mode programmable pacemaker.